Inactive Instrument

News Cadila Healthcare Limited NSE India S.E.

Equities

INE010B01019

End-of-day quote NSE India S.E. Other stock markets
- ^INR	-

Apr. 01	Zydus Receives Approval from WHO International Non-Proprietary Names for Usnoflast as Recommended Name for ZYIL1	CI
Mar. 28	Zydus Gets Four Observations from US FDA for Oncology Injectable Plant	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Zydus Receives Approval from WHO International Non-Proprietary Names for Usnoflast as Recommended Name for ZYIL1	Apr. 01	CI
Zydus Gets Four Observations from US FDA for Oncology Injectable Plant	Mar. 28	MT
Zydus Lifesciences Limited Receives Tentative Approval from USFDA for Letermovir Tablets, 240 Mg and 480 Mg	Mar. 23	CI
Zydus Lifesciences Gets US FDA's Final Nod for Finasteride and Tadalafil Capsules	Mar. 17	MT
Zydus Lifesciences Limited Receives Final Approval from USFDA and 180 Days CGT Exclusivity for Finasteride and Tadalafil Cap Capsules	Mar. 16	CI
Tranche Update on Zydus Lifesciences Limited's Equity Buyback Plan announced on February 9, 2024.	Mar. 15	CI
Zydus Lifesciences Gets US FDA Final Nod for Chlorpromazine Hydrochloride Injection; Shares Jump 3%	Mar. 14	MT
Zydus Receives Final Approval from the USFDA for Chlorpromazine Hydrochloride Injection USP, 25 mg/mL and 50 mg/2 mL (25 mg/mL), Single-Dose Vials	Mar. 14	CI
Zydus Receives Tentative Approval from the USFDA for Edaravone Injection, 30 mg/100 mL (0.3 mg/mL), Single-Dose Vial	Mar. 14	CI
Zydus Lifesciences Launches Generic Cancer Drug Ibyra in India	Mar. 13	MT
Zydus Lifesciences Limited Launches IBYRA, the Generic Version of Olaparib	Mar. 13	CI
Zydus Lifesciences Gets US FDA's EIR for Ahmedabad, India Unit's Inspection	Mar. 11	MT
Zydus Lifesciences Limited's Equity Buyback announced on February 9, 2024, has closed with 5,970,149 shares, representing 0.59% for INR 6,000 million.	Mar. 05	CI
Zydus Lifesciences Forms UAE-Based Arm	Feb. 22	MT
Zydus Lifesciences Limited Announces Incorporation of Wholly Owned Subsidiary Company	Feb. 22	CI
Zydus Lifesciences Gets US FDA Final Approval for Generic Chest Pain Drug	Feb. 16	MT
Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration for Isosorbide Mononitrate Extended-Release, Tablets USP, 30 mg, 60 mg, and 120 mg	Feb. 16	CI
Jefferies Adjusts Zydus Lifesciences’ Price Target to INR750 From INR660, Keeps at Hold	Feb. 12	MT
Zydus Lifesciences' Consolidated Net Profit Increases in Fiscal Q3; Shares Jump 7%	Feb. 12	MT
Transcript : Zydus Lifesciences Limited, Q3 2024 Earnings Call, Feb 09, 2024	Feb. 09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cadila Healthcare Limited NSE India S.E.

Equities

INE010B01019

Summary

Filters